IGC Pharma (IGC) Cash from Financing Activities (2010 - 2025)
IGC Pharma (IGC) reported Cash from Financing Activities of $3.1 million for Q3 2025, up 291.69% year-over-year from $794000.0 in Q3 2024, and up 265.45% quarter-over-quarter from $851000.0 in Q2 2025.
IGC Pharma (IGC) Cash from Financing Activities (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has 16 years of Cash from Financing Activities data on file, last reported at $3.1 million in Q3 2025.
- Cash from Financing Activities for Q3 2025 came in at $3.1 million, up 291.69% year-over-year; the trailing twelve-month figure through Sep 2025 was $5.1 million (up 28.84% YoY), and the FY2026 annual result was $710000.0, down 84.05% from the prior year.
- Cash from Financing Activities improved to $3.1 million in Q3 2025 per IGC's latest filing, from $851000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $14.2 million in Q1 2021 and troughed at -$1000.0 in Q4 2021.
- A 5-year average of $1.7 million and a median of $696500.0 in 2021 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities sank 100.14% in 2022, then jumped 250800.0% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at -$1000.0 in 2021, then jumped by 10300.0% to $102000.0 in 2022, then slumped by 100.98% to -$1000.0 in 2023, then surged by 34600.0% to $345000.0 in 2024, then soared by 801.45% to $3.1 million in 2025.
- Business Quant data shows IGC's Cash from Financing Activities at $3.1 million in Q3 2025, $851000.0 in Q2 2025, and $805000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 85,464.43 |
| 10 | IGC Pharma | 28.11 Mn | 27.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.11 Mn |
| Sep 30, 2025 | 3.11 Mn |
| Jun 30, 2025 | 851,000.00 |
| Jun 30, 2025 | 851,000.00 |
| Mar 31, 2025 | 805,000.00 |
| Mar 31, 2025 | 805,000.00 |
| Dec 31, 2024 | 345,000.00 |
| Dec 31, 2024 | 345,000.00 |
| Sep 30, 2024 | 794,000.00 |
| Sep 30, 2024 | 794,000.00 |
| Jun 30, 2024 | 2.51 Mn |
| Jun 30, 2024 | 2.51 Mn |
| Mar 31, 2024 | 667,000.00 |
| Mar 31, 2024 | 667,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | 2.86 Mn |
| Sep 30, 2023 | 2.86 Mn |
| Jun 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -1,000.00 |